Genome response to tissue plasminogen activator in experimental ischemic stroke

BMC Genomics

Volumn 11, Issue 1, 2010, Pages

  Jickling, Glen C ^a   Zhan, Xinhua ^a   Ander, Bradley P ^a   Turner, Renée J ^a   Stamova, Boryana ^a   Xu, Huichun ^a   Tian, Yingfang ^a   Liu, Dazhi ^a   Davis, Ryan R ^a   Lapchak, Paul A ^b   Sharp, Frank R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD VESSEL; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENOME ANALYSIS; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; REPERFUSION; ANIMAL; BLOOD BRAIN BARRIER; CHEMICALLY INDUCED DISORDER; GENETICS; IMMUNOLOGY; LEUKOCYTE; METABOLISM; SPRAGUE DAWLEY RAT; STROKE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; GENE EXPRESSION PROFILING; LEUKOCYTES; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77951052676     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-11-254     Document Type: Article

References (35)

1. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359(13):1317-1329. 10.1056/NEJMoa0804656, 18815396.
2. Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry 2008, 79(10):1093-1099. 10.1136/jnnp.2007.133371, 18223014.
3. Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis 2007, 24(1):1-10. 10.1159/000103110, 17519538.
4. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000, 31(12):3034-3040.
5. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci 2009, 32(1):48-55. 10.1016/j.tins.2008.09.006, 18963068.
6. Kidwell CS, Latour L, Saver JL, Alger JR, Starkman S, Duckwiler G, Jahan R, Vinuela F, Kang DW, Warach S. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis 2008, 25(4):338-343. 10.1159/000118379, 18303253.
7. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, Lo EH. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004, 35(11 Suppl 1):2726-2730. 10.1161/01.STR.0000143219.16695.af, 15459442.
8. Tang Y, Xu H, Du X, Lit L, Walker W, Lu A, Ran R, Gregg JP, Reilly M, Pancioli A, et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab 2006, 26(8):1089-1102. 10.1038/sj.jcbfm.9600264, 16395289.
9. Tang Y, Lu A, Aronow BJ, Sharp FR. Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease. Ann Neurol 2001, 50(6):699-707. 10.1002/ana.10042, 11761467.
10. Moore DF, Li H, Jeffries N, Wright V, Cooper RA, Elkahloun A, Gelderman MP, Zudaire E, Blevins G, Yu H, et al. Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation 2005, 111(2):212-221. 10.1161/01.CIR.0000152105.79665.C6, 15630028.
11. Du X, Tang Y, Xu H, Lit L, Walker W, Ashwood P, Gregg JP, Sharp FR. Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. Genomics 2006, 87(6):693-703. 10.1016/j.ygeno.2006.02.003, 16546348.
12. Xu H, Tang Y, Liu DZ, Ran R, Ander BP, Apperson M, Liu XS, Khoury JC, Gregg JP, Pancioli A, et al. Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke. J Cereb Blood Flow Metab 2008, 28(7):1320-1328. 10.1038/jcbfm.2008.22, 18382470.
13. Lit L, Sharp FR, Apperson M, Liu DZ, Walker WL, Liao I, Xu H, Ander BP, Wong B. Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy. Pharmacogenomics J 2009, 9(6):411-418. 10.1038/tpj.2009.22, 19488064.
14. Strbian D, Kovanen PT, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ. An emerging role of mast cells in cerebral ischemia and hemorrhage. Ann Med 2009, 1-13.
15. Strbian D, Karjalainen-Lindsberg ML, Kovanen PT, Tatlisumak T, Lindsberg PJ. Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke. Circulation 2007, 116(4):411-418. 10.1161/CIRCULATIONAHA.106.655423, 17606844.
16. Cuadrado E, Ortega L, Hernandez-Guillamon M, Penalba A, Fernandez-Cadenas I, Rosell A, Montaner J. Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J Leukoc Biol 2008, 84(1):207-214. 10.1189/jlb.0907606, 18390930.
17. Roelofs JJ, Rouschop KM, Leemans JC, Claessen N, de Boer AM, Frederiks WM, Lijnen HR, Weening JJ, Florquin S. Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J Am Soc Nephrol 2006, 17(1):131-140. 10.1681/ASN.2005010089, 16291841.
18. Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, Chan PH, Park TS. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 2005, 289(2):H558-568. 10.1152/ajpheart.01275.2004, 15764676.
19. Gautier S, Ouk T, Petrault O, Caron J, Bordet R. Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia. Br J Pharmacol 2009, 156(4):673-679. 10.1111/j.1476-5381.2009.00068.x, 2697703, 19210512.
20. Zhang RL, Zhang ZG, Chopp M, Zivin JA. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 1999, 30(3):624-629.
21. Zhang RL, Zhang C, Zhang L, Roberts C, Lu M, Kapke A, Cui Y, Ninomiya M, Nagafuji T, Albala B, et al. Synergistic effect of an endothelin type A receptor antagonist, S-with rtPA on the neuroprotection after embolic stroke. Stroke 2008, 39(10):2830-2836. 10.1161/STROKEAHA.108.515684, 2740650, 18669895.
22. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003, 112(10):1533-1540. 259131, 14617754.
23. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003, 9(10):1313-1317. 10.1038/nm926, 12960961.
24. Hiu T, Nakagawa S, Hayashi K, Kitagawa N, Tsutsumi K, Kawakubo J, Honda M, Suyama K, Nagata I, Niwa M. Tissue plasminogen activator enhances the hypoxia/reoxygenation-induced impairment of the blood-brain barrier in a primary culture of rat brain endothelial cells. Cell Mol Neurobiol 2008, 28(8):1139-1146. 10.1007/s10571-008-9294-x, 18629628.
25. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 2008, 39(12):3372-3377. 10.1161/STROKEAHA.108.514026, 18927459.
26. Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology 2006, 66(10):1550-1555. 10.1212/01.wnl.0000216133.98416.b4, 16717217.
27. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007, 27(4):697-709.
28. Liu XS, Zhang ZG, Zhang L, Morris DC, Kapke A, Lu M, Chopp M. Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection. J Cereb Blood Flow Metab 2006, 26(6):787-796. 10.1038/sj.jcbfm.9600227, 16177809.
29. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 2007, 54(1):34-66. 10.1016/j.brainresrev.2006.11.003, 17222914.
30. Molina CA, Alvarez-Sabin J. Recanalization and reperfusion therapies for acute ischemic stroke. Cerebrovasc Dis 2009, 27(Suppl 1):162-167. 10.1159/000200455, 19342847.
31. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989, 20(1):84-91.
32. Andersen M, Overgaard K, Meden P, Boysen G, Choi SC. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 1999, 30(7):1464-1471.
33. Gautier S, Petrault O, Gele P, Laprais M, Bastide M, Bauters A, Deplanque D, Jude B, Caron J, Bordet R. Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. Stroke 2003, 34(12):2975-2979. 10.1161/01.STR.0000101914.62066.7B, 14615621.
34. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19(2):185-193. 10.1093/bioinformatics/19.2.185, 12538238.
35. Tibshirani RJ, Efron B. Pre-validation and inference in microarrays. Stat Appl Genet Mol Biol 2002, 1:Article1.